(R)-2-amino-N1-((2R,3R)-1-((R)-2-((2R,3S)-3-((2R,3R)-1-((R)-1-((R)-2-((R)-2-carbamoylpyrrolidine-1-carbonyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylamino)-3-methyl-1-oxopentan-2-ylcarbamoyl)-2-hydroxy-5-methylhexyl)pyrrolidin-1-yl)-3-methyl-1-oxopentan-2-yl)pentanediamide

ID: ALA3237162

Chembl Id: CHEMBL3237162

PubChem CID: 90671287

Max Phase: Preclinical

Molecular Formula: C44H77N9O9

Molecular Weight: 876.15

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC[C@@H](C)[C@@H](NC(=O)[C@@H](CC(C)C)[C@H](O)C[C@H]1CCCN1C(=O)[C@H](NC(=O)[C@H](N)CCC(N)=O)[C@H](C)CC)C(=O)N[C@@H](C(=O)N1CCC[C@@H]1C(=O)N1CCC[C@@H]1C(N)=O)C(C)C

Standard InChI:  InChI=1S/C44H77N9O9/c1-9-26(7)36(41(59)48-35(25(5)6)43(61)53-21-13-16-32(53)42(60)52-20-12-15-31(52)38(47)56)49-39(57)29(22-24(3)4)33(54)23-28-14-11-19-51(28)44(62)37(27(8)10-2)50-40(58)30(45)17-18-34(46)55/h24-33,35-37,54H,9-23,45H2,1-8H3,(H2,46,55)(H2,47,56)(H,48,59)(H,49,57)(H,50,58)/t26-,27-,28-,29+,30-,31-,32-,33-,35-,36-,37-/m1/s1

Standard InChI Key:  NSRVLTHYFKBEBP-MCYVQDQOSA-N

Associated Targets(non-human)

prt Protease (104 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 876.15Molecular Weight (Monoisotopic): 875.5844AlogP: 0.65#Rotatable Bonds: 23
Polar Surface Area: 280.66Molecular Species: NEUTRALHBA: 10HBD: 7
#RO5 Violations: 2HBA (Lipinski): 18HBD (Lipinski): 10#RO5 Violations (Lipinski): 3
CX Acidic pKa: 12.04CX Basic pKa: 7.92CX LogP: -0.16CX LogD: -0.80
Aromatic Rings: Heavy Atoms: 62QED Weighted: 0.08Np Likeness Score: 0.08

References

1. Awahara C, Tatsumi T, Furuta S, Shinjoh G, Konno H, Nosaka K, Kobayashi K, Hattori Y, Akaji K..  (2014)  Effect of prime-site sequence of retro-inverso-modified HTLV-1 protease inhibitor.,  22  (8): [PMID:24680060] [10.1016/j.bmc.2014.02.050]

Source